Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological respon...
Main Authors: | Hao Long, Si Chen, Hui Yu, Wen-Yu Zhai, Ze-Rui Zhao, Yao-Bin Lin, Yi-Zhi Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-09-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/9/e005160.full |
Similar Items
-
Lymph node targeting for immunotherapy
by: Y. Wang, et al.
Published: (2023-12-01) -
INFLUENCE OF NEOADJUVANT THERAPY ON THE RATIO OF LYMPH NODES
by: Laura CREDIDIO, et al.
Published: (2024-03-01) -
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
by: Ze-Rui Zhao, et al.
Published: (2021-01-01) -
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
by: Lanyi Nora Chen, et al.
Published: (2023-03-01) -
Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
by: Hee Jun Choi, et al.
Published: (2022-11-01)